JAK inhibitors and other oral immunology drugs on SilverScript Choice (S5601-050)
Rinvoq, Xeljanz, Olumiant and Otezla, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Iowa + 6 more
- Premium
- $29.70/month
- Deductible
- $615.00
3 of 5 JAK inhibitors are covered on this plan. All 3 require prior authorization.
2 aren't on the formulary (Olumiant and Otezla).
- from $1,627.94Tier 5
- from $1,125.33Tier 5
- $1,755.35Tier 5
Not on the formulary
Olumiant, Otezla
Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.